RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional ...

Approves Merck’s CAPVAXIVE® for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults Business Wire • 12 days ago Merck Enters Exclusive License Agreement for HRS-5346, an ...

meningitidis military personnel who are at increased risk of meningococcal disease close contacts of a case of IMD and for individuals at risk in an outbreak setting if the disease is caused by a ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best mid cap ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Health officials prepare to administer a vaccine ...

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults Rahway: Merck, ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...